STOCK TITAN

Adaptive Biotechnologies Corp (ADPT) officer exercises 105,762 options and sells 105,762 shares

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp Chief People Officer Francis Lo exercised employee stock options covering 105,762 common shares at exercise prices of $7.80, $8.46 and $12.14, and sold 105,762 shares of common stock at a weighted average price of $22.59 on July 15, 2026.

After these transactions, he directly held 230,713 common shares and indirectly held 2,500 shares through his spouse. All transactions were effected under a Rule 10b5-1 trading plan adopted on September 15, 2025.

Positive

  • None.

Negative

  • None.
Insider LO FRANCIS
Role Chief People Officer
Sold 105,762 shs ($2.39M)
Type Security Shares Price Value
Exercise Stock Option (right to buy) 59,374 $0.00 --
Exercise Stock Option (right to buy) 23,677 $0.00 --
Exercise Stock Option (right to buy) 22,711 $0.00 --
Exercise Common Stock 59,374 $7.80 $463K
Exercise Common Stock 23,677 $12.14 $287K
Exercise Common Stock 22,711 $8.46 $192K
Sale Common Stock 105,762 $22.59 $2.39M
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct); Common Stock — 290,087 shares (Direct); Common Stock — 2,500 shares (Indirect, By You Jin Lee (spouse))
Footnotes (1)
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.49 to $22.78, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The option is fully vested and exercisable. The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Shares sold 105,762 shares of Common Stock Sale on July 15, 2026 at weighted average price
Weighted average sale price $22.59 per share Common Stock sale; individual prices $22.49–$22.78
Options exercised (shares) 105,762 shares Total underlying shares from three Stock Option exercises
Option strike prices $7.80, $8.46, $12.14 per share Exercise prices for Stock Option (right to buy) awards
Direct holdings after transactions 230,713 shares Common Stock directly owned by Francis Lo after July 15, 2026
Indirect holdings after transactions 2,500 shares Common Stock held indirectly through spouse You Jin Lee
Rule 10b5-1 plan adoption date September 15, 2025 Trading plan governing the reported option exercises and sale
Rule 10b5-1 trading plan regulatory
"transactions were effected pursuant to a Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported for this transaction is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy) with underlying Common Stock"
indirect ownership financial
"ownership type marked indirect, nature of ownership: By You Jin Lee (spouse)"
exercise or conversion of derivative security financial
"transaction_code M described as Exercise or conversion of derivative security"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transactions did Adaptive Biotechnologies (ADPT) report for Francis Lo on July 15, 2026?

On July 15, 2026, Chief People Officer Francis Lo exercised options and sold company stock. He exercised options for 105,762 shares at strikes of $7.80, $8.46 and $12.14, and sold 105,762 common shares at a weighted average of $22.59.

How many Adaptive Biotechnologies (ADPT) shares does Francis Lo hold after the reported transactions?

After the reported activity, Francis Lo directly held 230,713 Adaptive Biotechnologies common shares. He also had indirect ownership of 2,500 additional shares through his spouse, as disclosed, giving investors clarity on both his direct and family-related positions.

Were Francis Lo’s Adaptive Biotechnologies (ADPT) share transactions under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 trading plan. The plan was adopted on September 15, 2025, indicating these exercises and the sale followed a pre-established, automated trading arrangement.

At what prices were Francis Lo’s Adaptive Biotechnologies (ADPT) stock options exercised and shares sold?

Lo exercised options with strike prices of $7.80, $8.46 and $12.14 per share. He sold 105,762 common shares at a weighted average of $22.59, with individual sale prices ranging from $22.49 to $22.78.

How many Adaptive Biotechnologies (ADPT) shares did Francis Lo sell in the latest insider transaction?

Francis Lo sold 105,762 Adaptive Biotechnologies common shares. The sale occurred on July 15, 2026, at a weighted average price of $22.59 per share, in multiple transactions within a price range of $22.49–$22.78.

What happened to Francis Lo’s stock options in Adaptive Biotechnologies (ADPT) on July 15, 2026?

On July 15, 2026, Lo exercised employee stock options for 105,762 shares of common stock. The exercised options had strikes of $7.80, $8.46 and $12.14, and some option positions were reduced to 0 or lowered balances after exercise.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LO FRANCIS

(Last)(First)(Middle)
C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION
1165 EASTLAKE AVENUE EAST

(Street)
SEATTLE WASHINGTON 98109

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief People Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/15/2026M(1)59,374A$7.8290,087D
Common Stock07/15/2026M(1)23,677A$12.14313,764D
Common Stock07/15/2026M(1)22,711A$8.46336,475D
Common Stock07/15/2026S(1)105,762D$22.59(2)230,713D
Common Stock2,500IBy You Jin Lee (spouse)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$7.807/15/2026M(1)59,374 (3)05/06/2029Common Stock59,374$00D
Stock Option (right to buy)$12.1407/15/2026M(1)23,677 (3)03/04/2032Common Stock23,677$0132,246D
Stock Option (right to buy)$8.4607/15/2026M(1)22,711 (4)03/06/2033Common Stock22,711$037,511D
Explanation of Responses:
1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.49 to $22.78, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
3. The option is fully vested and exercisable.
4. The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
/s/ Francis Lo by Kyle Piskel, Attorney-in-Fact07/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)